Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers: AI-Powered Healthcare Disruption
12:38am, Sunday, 09'th Mar 2025
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company's subscriber base reached 2.2 million, growin
Hims & Hers to shut down dermatology business Apostrophe
06:21pm, Friday, 07'th Mar 2025
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.
Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
03:24pm, Friday, 07'th Mar 2025
Hims and Hers is shutting down the dermatology business it acquired in 2021, BI has learned. The company said it's closing skincare site Apostrophe to centralize its teledermatology offerings.
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
09:05am, Friday, 07'th Mar 2025
Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% increas
This Could Be a Huge Blow to Hims & Hers Health Stock
06:15am, Friday, 07'th Mar 2025
Hims & Hers Health (HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% during that stretch. By focusing on offering customers personalized telehealth
Why Hims & Hers Stock Just Collapsed
12:15pm, Thursday, 06'th Mar 2025
Hims & Hers Health (HIMS -12.33%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas.
Healthcare Stock Could Be Good 'Buy the Dip' Play
12:17pm, Wednesday, 05'th Mar 2025
The shares of healthcare name Hims & Hers Health Inc (NYSE:HIMS) have retreated from their Feb. 19, pre-earnings all-time high of $72.98.
Novo Nordisk's Cheaper Wegovy Offering Is Bad News for Hims & Hers
10:56am, Wednesday, 05'th Mar 2025
The announcement comes weeks after the FDA declared that Wegovy is no longer in shortage.
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
10:37am, Wednesday, 05'th Mar 2025
Hims & Hers Health, Inc. HIMS stock is trading lower on Wednesday, with a session volume of 7.7 million compared to the average volume of 19.34 million, as per data from Benzinga Pro.
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
11:47am, Monday, 03'rd Mar 2025
HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a
Hims & Hers: A Generational Dip-Buying Opportunity
09:30am, Sunday, 02'nd Mar 2025
HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While bears
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
07:10am, Saturday, 01'st Mar 2025
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (HIMS 9.07%) plummeted following its fourth-quarter earnings report. The stock had rocke
Why Hims & Hers Health Stock Sank This Week
02:54pm, Friday, 28'th Feb 2025
Shares of Hims & Hers Health (HIMS 6.76%) sank 10.5% this week, according to data from S&P Global Market Intelligence. The telehealth company that sells dermatology, sexual health, and weight loss dru
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Friday, 28'th Feb 2025
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers: Shortage-Driven Sell-Off Appears Overdone; Buy
06:39am, Thursday, 27'th Feb 2025
Hims and Hers' stock dropped 25% due to the end of the semaglutide shortage, but the sell-off is seen as exaggerated. Despite the setback, Hims and Hers continue to show strong subscriber growth and p
